Patient Recruitment and Late-Stage Research Companies Merge
Leading healthcare firms Blue Chip Patient Recruitment and J Trotter Research & Consulting combine to form Continuum Clinical.
Suburban Chicago-based healthcare firms Blue Chip Patient Recruitment (BCPR) and J Trotter Research & Consulting (JTRC) have merged to form Continuum Clinical. The new company combines the BCPR specialty of patient recruitment for clinical trials and the JTRC expertise of late-stage (post-approval) research, and will also offer medical communications services.
“Continuum Clinical is uniquely positioned in the market to provide three distinct, yet interrelated services to pharmaceutical and medical device companies,” said Jeff Trotter, the president of Continuum. “This new venture represents a convergence of services and robust capabilities that respond to the increasingly aligned needs of clinical researchers and product commercialization professionals.”
Continuum will capitalize on BCPR’s twenty years of experience recruiting patients for over 600 clinical trials, as well as its communication, public relations, digital, advertising and media buying capabilities. In addition, Continuum builds on JTRC’s thirty-year legacy in health economics and outcomes research, observational studies and patient registries, and an extensive track record of publications.
“We are excited to build upon our path of transformational growth by offering our current and potential clients even more depth of services,” said Neil Weisman, executive vice president and general manager of Continuum’s patient recruitment practice (which will retain the BCPR branding through 2014). “Our expanded platform will enhance our capabilities in both site and patient engagement in all phases of clinical research.”
By offering the three related services to major pharmaceutical and medical device clients, Continuum Clinical facilitates greater internal synergies and efficiencies in establishing and communicating the value of clients’ medical product innovations to physicians, patients, and payers.
“Our credentials with multiple stakeholders within our client companies is what sets us apart,” said Trotter. “And we are intimately familiar with both the challenges and the considerable opportunities that exist when commercial and clinical teams work together.”
The company will be headquartered in Northbrook, Ill., with staff located off-site in strategic locations globally.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
